



1B-365-C025

## Monoclonal Antibody to CD33 Biotin conjugated (0.025 mg)

Clone: HIM3-4

**Isotype:** Mouse IgG1

Specificity: The antibody HIM3-4 reacts with CD33, a 67 kDa type I transmembrane

glycoprotein (immunoglobulin superfamily) expressed on myeloid progenitors, monocytes, granulocytes, dendritic cells and mast cells; it is absent on platelets,

lymphocytes, erythrocytes and hematopoietic stem cells.

HLDA V; WS Code M MA112 HLDA VI; WS Code M MA47

Regulatory Status: RUO

Immunogen: NFMY-9s human cell line

Species Reactivity: Human, Non-Human Primates

**Preparation:** The purified antibody is conjugated with Biotin-LC-NHS under optimum conditions.

The reagent is free of unconjugated biotin.

Concentration: 1 mg/ml

Storage Buffer: Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4

Storage / Stability: Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial

label.

**Usage:** Biotinylated antibody is designed for indirect immunofluorescence analysis by Flow

Cytometry.

Suggested working dilution is 1:1000. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the

investigator.

**Expiration**: See vial label

Lot Number: See vial label

Background: CD33 is a transmembrane protein of the sialic acid-binding immunoglobulin-like

lectin (Siglec) family. It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies; these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface. CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia.



## PRODUCT DATA SHEET

## References:

\*Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML: The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol. 1999 Nov;29(11):3440-9.

\*Walter RB, Häusermann P, Raden BW, Teckchandani AM, Kamikura DM, Bernstein ID, Cooper JA: Phosphorylated ITIMs Enable Ubiquitylation of an Inhibitory Cell Surface Receptor. Traffic. 2007 Dec 18

\*Orr SJ, Morgan NM, Elliott J, Burrows JF, Scott CJ, McVicar DW, Johnston JA: CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood. 2007 Feb 1;109(3):1061-8.

\*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995). \*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997). \*McCormack E, Mujic M, Osdal T, Bruserud O, Gjertsen BT: Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 2013 Feb 14;121(7):e34-42. doi: 10.1182/blood-2012-05-429555.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.